Lead Product(s): TRS02
Therapeutic Area: Ophthalmology Product Name: TRS02
Highest Development Status: IND Enabling Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2021
In the Pre-IND meeting, Tarsier Pharma received FDA's guidance regarding the CMC requirements for slow-release formulation of TRS02. Clarity regarding bridging nonclinical studies requirements and clinical strategy were also obtained.